Laura Hagerty

Dr. Hagerty has spent more than a decade pursuing therapies for muscular dystrophy. She began her career in drug development as a preclinical pharmacologist with Acceleron Pharma and later with the Skeletal Muscle Metabolism Discovery Unit at GlaxoSmithKline. Prior to joining ReveraGen, she served as Scientific Portfolio Director at Muscular Dystrophy Association where she managed strategic investment in basic and translational research for Duchenne and related muscular dystrophies. Dr. Hagerty received her B.S. in Chemistry from Allegheny College and her Ph.D. in Pharmacology from Duke University.